BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12943479)

  • 1. Pharmacotherapy of essential thrombocythaemia: economic considerations.
    Griesshammer M; Langer C
    Expert Opin Pharmacother; 2003 Sep; 4(9):1499-505. PubMed ID: 12943479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment practice for essential thrombocythaemia in adults.
    Griesshammer M; Bangerter M; Grünewald M
    Expert Opin Pharmacother; 2001 Mar; 2(3):385-93. PubMed ID: 11336593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness considerations in the treatment of essential thrombocythemia.
    Golub R; Adams J; Dave S; Bennett CL
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):28-32. PubMed ID: 12096355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential thrombocythaemia in children: is a treatment needed?
    Randi ML; Putti MC
    Expert Opin Pharmacother; 2004 May; 5(5):1009-14. PubMed ID: 15155103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on diagnosis and management of essential thrombocythemia.
    Gisslinger H
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):430-6. PubMed ID: 16810619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term management of thrombocytosis in essential thrombocythaemia.
    Birgegård G
    Ann Hematol; 2009 Jan; 88(1):1-10. PubMed ID: 18629498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers?
    Bennett CL; Weinberg PO; Golub RM
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):26-9. PubMed ID: 9930555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
    Gotic M; Egyed M; Gercheva L; Warzocha K; Kvasnicka HM; Achenbach H; Wu J
    Cardiovasc Toxicol; 2021 Mar; 21(3):236-247. PubMed ID: 33123978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical approach to treating essential thrombocythaemia: case studies.
    Reilly JT
    Eur J Haematol Suppl; 2007 Oct; (68):40-2. PubMed ID: 17727566
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
    Kiladjian JJ; Besses C; Griesshammer M; Gugliotta L; Harrison C; Coll R; Smith J; Birgegård G
    Clin Drug Investig; 2013 Jan; 33(1):55-63. PubMed ID: 23184668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Primary thrombocythemia: diagnosis and therapy].
    Petrides PE
    Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
    Petrides PE
    Expert Opin Pharmacother; 2004 Aug; 5(8):1781-98. PubMed ID: 15264993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of patients with essential thrombocythemia: current concepts and perspectives.
    Briere J; Guilmin F
    Pathol Biol (Paris); 2001 Mar; 49(2):178-83. PubMed ID: 11317966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anagrelide: what was new in 2004 and 2005?
    Petrides PE
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anagrelide: a review of its use in the management of essential thrombocythaemia.
    Wagstaff AJ; Keating GM
    Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of essential thrombocythemia].
    Costello R; O'Callaghan T; Sébahoun G
    Rev Med Interne; 2005 Dec; 26(12):947-55. PubMed ID: 16122842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.